Dyslipidemia and biological agents among a sample of patients attending Baghdad Teaching Hospital | ||
| IRAQI JOURNALOF COMMUNITY MEDICINE | ||
| Article 1, Volume 29, Issue 3, September 2016, Pages 129-132 | ||
| Authors | ||
| Atta AH Mousa; Ali Hussein; Nazar Abdull Latif | ||
| Abstract | ||
| Background: Tumor necrosis factor-alpha (TNF-α) is a multifunctional pro-inflammatory cytokine that had a major role in the etio-pathogenesis of psoriasis and psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease (IBD), and other dermatologic and rheumatologic conditions. A new era in the treatment of rheumatic diseases began with the development of TNF-α-inhibitors Objectives: To evaluate lipid profile changes after anti-TNF therapy in patients with psoriatic, rheumatoid arthritis and ankylosing spondylitis Patients & Methods: A prospective study included 90 patients presenting with ((30) Psoriatic arthritis, (30) ankylosing spondylitis (30) rheumatoid arthritis (who were treated with anti-TNF therapy (infliximab, rituxmab etanercept) and assessed during follow-up period after 6month of therapy. Results: Regarding (TC,TG, HDL and LDL) Significance differences(p<0.000) were seen after biological therapy with infliximab infusion in patients with psoriatic arthritis , The current study had Significance differences regarding TG and HDL after 6 month of treatment of rheumatoid arthritis patients with rituximab., Significance differences were seen regarding TG and LDL in ankylosing spodylitis patients treated with etanercept Conclusion: Significance differences were seen regarding lipid profile and antitumor necrosis factor alpha therapy regarding psoriatic ,Rheumatoid arthritis and ankylosing spondylitis | ||
| Keywords | ||
| Dyslipidemia; psoriatic arthritis; Rheumatoid arthritis | ||
|
Statistics Article View: 48 PDF Download: 16 |
||